The evolving role of PARP inhibitors in advanced ovarian cancer
Authors
Aglaia Skolariki
Department of Medical Oncology, Papageorgiou General Hospital, Thessaloniki, Greece
Eleni Sogka
Department of Medical Oncology, Papageorgiou General Hospital, Thessaloniki, Greece
Alexandros Bokas
1st Department of Medical Oncology, Theagenion Hospital, Thessaloniki, Greece
Avraam Assi
2nd Department of Medical Oncology, Henry Dunant Hospital Center, Athens, Greece
Marianna K. Pispirigou
Division of Oncology, Department of Internal Medicine, University Hospital of Patras, Greece
Panagiotis Koliou
Royal Surrey NHS Foundation Trust, Guildford, United Kingdom
Language: English
Page range: 82 - 104
Submitted on: Jan 2, 2021
Accepted on: Feb 18, 2021
Published on: Aug 9, 2021
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2021 Sofia Levva, Aglaia Skolariki, Eleni Sogka, Alexandros Bokas, Avraam Assi, Marianna K. Pispirigou, Panagiotis Koliou, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.